Nayak, RC; Hegde, S; Althoff, MJ; Wellendorf, AM; Mohmoud, F; Perentesis, J; Reina-Campos, M; Reynaud, D; Zheng, Y; Diaz-Meco, MT; et al.
The signaling axis atypical protein kinase C lambda/iota-Satb2 mediates leukemic transformation of B-cell progenitors.
Nature Communications.
2019;
10.
Wunderlich, M; Manning, N; Sexton, C; Sabulski, A; Byerly, L; O'Brien, E; Perentesis, JP; Mizukawa, B; Mulloy, JC.
Improved chemotherapy modeling with RAG-based immune deficient mice.
PLoS ONE.
2019;
14:e0225532-e0225532.
Melgar, K; Walker, MM; Jones, LM; Bolanos, LC; Hueneman, K; Wunderlich, M; Jiang, J; Wilson, KM; Zhang, X; Sutter, P; et al.
Overcoming adaptive therapy resistance in AML by targeting immune response pathways.
Science Translational Medicine.
2019;
11:eaaw8828-eaaw8828.
Widemann, BC; Lu, Y; Reinke, D; Okuno, SH; Meyer, CF; Cote, GM; Chugh, R; Milhem, MM; Hirbe, AC; Kim, A; et al.
Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016).
Sarcoma.
2019;
2019:1-8.
Sertorio, M; Perentesis, JP; Vatner, RE; Mascia, AE; Zheng, Y; Wells, SI.
Cancer cell metabolism: Implications for x-ray and particle radiation therapy.
International journal of particle therapy.
2019;
5:40-48.